- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
Patent holdings for IPC class C07D 237/04
Total number of patents in this class: 140
10-year publication summary
|
10
|
10
|
11
|
9
|
7
|
10
|
8
|
8
|
5
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Broad Institute, Inc. | 1715 |
12 |
| Dana-Farber Cancer Institute, Inc. | 2539 |
8 |
| Theravance Biopharma R&D IP, LLC | 518 |
8 |
| Bayer Pharma AG | 1086 |
7 |
| Bayer AG | 3226 |
6 |
| Araxes Pharma LLC | 89 |
5 |
| The General Hospital Corporation | 4659 |
4 |
| Lantheus Medical Imaging, Inc. | 172 |
4 |
| F. Hoffmann-La Roche AG | 7961 |
3 |
| Massachusetts Institute of Technology | 9932 |
3 |
| JSR Corporation | 2483 |
3 |
| Chugai Seiyaku Kabushiki Kaisha | 1319 |
3 |
| Otsuka Pharmaceutical Co., Ltd. | 1544 |
3 |
| Hoffmann-La Roche Inc. | 3303 |
2 |
| Boehringer Ingelheim International GmbH | 4754 |
2 |
| Janssen Pharmaceutica N.V. | 3606 |
2 |
| Syngenta Participations AG | 3026 |
2 |
| Anhui New Star Pharmaceutical Development Co., Ltd. | 13 |
2 |
| The Arizona Board of Regents on Behalf of the University of Arizona | 2082 |
2 |
| FMC Corporation | 851 |
2 |
| Other owners | 57 |